Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Screening platform · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | OTHER | Participants with NSCLC will be screened for biomarker eligibility for a linked Roche study. |
| Name | Type | Description |
|---|---|---|
| Screening platform | OTHER | The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing. |
General Inclusion Criteria: * Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol * Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal produ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
The Roche screening platform is a Phase 2 screening study for participants with malignant tumors, specifically solid tumors. It is an uncontrolled, non-randomized trial that has been completed, with a total enrollment of 470 participants across multiple countries.
Roche Holding AG (ticker: RHHBY) is the developer of the screening platform. The platform is being investigated in the context of solid tumors, and the associated clinical trial has been completed.
The Roche screening platform is in Phase 2 of clinical development. The single trial associated with it, NCT05419375, has been completed, and the platform is not yet approved for any use.
The Roche screening platform is associated with one clinical trial, NCT05419375, titled "Screening Study for Participants With Malignant Tumors." This Phase 2 study enrolled 470 participants with solid tumors and has been completed.
The Roche screening platform is not a drug but a screening platform used to identify participants for clinical trials. It is being studied in the context of solid tumors, and its development is led by Roche Holding AG.